Related Experiment Video
Updated: Nov 20, 2025
06:54
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
11.5K
Prostate-specific Membrane Antigen Theranostics for Prostate Cancer Care: A Need to Prove Clinical Utility
Alec Paschalis1, Bertrand Tombal2, Johann S de Bono1
1The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
European Urology Focus
|January 26, 2021
Abstract:
Prostate-specific membrane antigen-based theranostics are likely to become important tools for the management of prostate cancer. However, data proving their clinical utility are urgently required before implementation of their use outside clinical trials, and their off-trial use needs to be better regulated.
